A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
Approximately 112 HIV-negative women, aged 18 to 50, will be enrolled in this multicenter
study at four sites. Volunteers will be randomized to dapivirine (TMC120) vaginal gel or
matching placebo gel. The volunteers will receive investigational product for a total of 42
days. Volunteers will be monitored on days 7, 28 and 42 for safety, tolerability and
compliance.